Advances in Antioxidative Therapy of Multiple Sclerosis
The DOI matches its Crossref record.
Abstract
Multiple sclerosis (MS) is a chronic, multifactorial disease of the central nervous system (CNS), typified by repetitive relapses and/or progression. The conventional treatment options in MS are limited. However, recently several new drugs have been introduced. Oxidative stress is a crucial factor in MS pathogenesis by ameliorating leukocyte migration, contributing to oligodendrocyte damage and axonal injury. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are created in CNS of MS patients mainly by activated macrophages and microglia structures responsible for demyelinisation and axons disruption. Activated microglia secretes different inflammatory and oxidative stress mediators such as cytokines (TNF and IL- 1b and IL- 6) and chemokines (macrophage inflammatory protein MIP- 1a, monocyte chemoattractant protein, MCP- 1 and interferon (IFN) inducible protein IP- 10). The inflammatory state is promoted by that. MS in chronic stages is dominated by neurogenerative processes involving axon and neuron loss probably resulting from oxidative stress and excitotoxicity. Therefore, consideration of the treatment engaging antioxidants and diet supplementation is needed. The present review describes the antioxidative system in CNS and possible antioxidative therapies in MS. Although some exogenous compounds have been proposed as such approach to MS treatment, there is a strong need for further research in this field. Such investigation is required for better understanding of the potential of protective effects of antioxidants in cellular immunology of MS neurodegeneration. Not only would that increase our knowledge about the disease mechanisms but also could help to establish new goals for innovative treatment methods and provide real therapeutic benefits in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Overview of General and Discriminating Markers of Differential Microglia Phenotypes
Jurga, A. M., Paleczna, M., & Kuter, K. Z. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00198 · Cited by 1,000
The role of microglia in multiple sclerosis
Luo, C., Jian, C., Liao, Y., Huang, Q., Wu, Y., Liu, X., Zou, D., & Wu, Y. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s140634 · Cited by 187
Albumin and multiple sclerosis
LeVine, S. M. (2016) · BMC Neurology · doi:10.1186/s12883-016-0564-9 · Cited by 105
Plasmalogen phospholipids protect internodal myelin from oxidative damage
Luoma, A. M., Kuo, F., Cakici, O., Crowther, M. N., Denninger, A. R., Avila, R. L., Brites, P., & Kirschner, D. A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.03.012 · Cited by 97
Song, X.-M., Yu, Q., Dong, X., Yang, H. O., Zeng, K.-W., Li, J., & Tu, P.-F. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.06.005 · Cited by 60
Metadata
- Authors
- Miller, E., & Wachowicz, B.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-11
- Volume
- 20
- Issue
- 37
- Pages
- 4720-4730
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W1997712262
- Cited by
- 50
- References
- 0
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in Antioxidative Therapy of Multiple Sclerosis. https://app.cochat.ai/papers/10.2174/09298673113209990156
- The paper
- Miller, E., & Wachowicz, B. (2013). Advances in Antioxidative Therapy of Multiple Sclerosis. Current Medicinal Chemistry. https://doi.org/10.2174/09298673113209990156
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.